Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits

被引:11
|
作者
Cam, Duygu [1 ]
Berk, Ayse Tulin [2 ]
Micili, Serap Cilaker [3 ]
Kume, Tuncay [4 ]
Ergur, Bekir Ugur [3 ]
Yilmaz, Osman [5 ]
机构
[1] State Hosp, Dept Ophthalmol, Tunceli, Turkey
[2] Dokuz Eylul Univ, Sch Med, Dept Ophthalmol, TR-14435210 Izmir, Turkey
[3] Dokuz Eylul Univ, Sch Med, Dept Histol & Embryol, Izmir, Turkey
[4] Dokuz Eylul Univ, Sch Med, Dept Biochem, Izmir, Turkey
[5] Dokuz Eylul Univ, Sch Med, Multidisciplinary Lab, Izmir, Turkey
关键词
Aflibercept; apoptosis; bevacizumab; ranibizumab; retinopathy of prematurity; VEGF inhibition; ENDOTHELIAL GROWTH-FACTOR; CELL-PROLIFERATION; PIGMENT EPITHELIUM; SUBRETINAL NEOVASCULARIZATION; DIABETIC-RETINOPATHY; VISUAL FUNCTION; SURVIVAL FACTOR; NERVOUS-SYSTEM; RPE CELLS; VEGF;
D O I
10.3109/02713683.2016.1164190
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To analyze the retinal effects of the intravitreally administered vascular endothelial growth factor (VEGF) inhibitors (aflibercept, bevacizumab and ranibizumab) in newborn rabbits.Methods: Right eyes of 28 two-week-old New Zealand albino rabbits comprised the study population. Four eyes received intravitreal injection of 0.025cc balanced salt solution (BSS) (group I, control group); six 0.25 mg ranibizumab (group II), six 0.3125 mg bevacizumab (group III), six 0.625 mg bevacizumab (group IV), and six 1 mg aflibercept (group V) intravitreally. Blood samples were obtained to evaluate serum VEGF levels. Retinal tissues were examined by light microscopy and immunohistochemical examination (TUNEL and caspase-3 staining) to evaluate the level of apoptosis at the end of the third week.Results: Light microscopic evaluation did not show any retinal abnormality in all study and control eyes. Positive TUNEL staining was present in 16.75 1.25%, 23.6 +/- 1.36%, 33.1 +/- 5.03%, 49.3 +/- 9.3%, and 32.33 +/- 8.06% of the eyes recruited in groups I, II, III, IV, and V, respectively. Mean percentage of apoptotic cell counts detected by caspase-3 staining was as follows: 6.75 +/- 2.06% in Group I, 12.6 +/- 13.44% in Group II, 15.5 +/- 1.37% in Group III, 24.0 +/- 2.7% in Group IV, and 17.33 +/- 1.96% in Group V. TUNEL and caspase-3 staining ratio was found to be statistically higher in all anti-VEGF drug groups compared to the controls (TUNEL stain; p = 0.01, p = 0.01, p = 0.01, p = 0.01; caspase-3 stain; p = 0.024, p = 0.009, p = 0.01, p = 0.01, respectively). Serum VEGF levels were 82.16 +/- 1.72 pg/mL, 54.53 +/- 12.69 pg/mL, 33.09 +/- 17.26 pg/mL, 39.66 +/- 5.77 pg/mL, and 36.90 +/- 28.14 pg/mL for the control groups II, III, IV, and V, respectively. Serum VEGF concentrations were found to be statistically lower in the anti-VEGF groups compared to the control eyes (p = 0.011, p = 0.011, p = 0.011, p = 0.014, respectively).Conclusion: This study demonstrates that apoptosis was induced in the retina of newborn rabbits by intravitreal administration of anti-VEGF agents together with reduction in serum VEGF levels. Among the three anti-VEGF agents, ranibizumab caused the least apoptotic activity in the retina and reduction in serum VEGF levels. In light of our study, we believe that intravitreal anti-VEGF agents should be used with caution as a first line treatment for the treatment of retinopathy of prematurity.
引用
收藏
页码:315 / 322
页数:8
相关论文
共 50 条
  • [21] Intraocular Pressure Changes after Intravitreal Bevacizumab or Ranibizumab Injection: A Retrospective Study
    Mansoori, Tarannum
    Agraharam, Satish Gooty
    Manwani, Sunny
    Balakrishna, Nagalla
    JOURNAL OF CURRENT OPHTHALMOLOGY, 2021, 33 (01): : 6 - 11
  • [22] Effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection
    Fujii, Ayaka
    Imai, Hisanori
    Kanai, Michiko
    Azumi, Atsushi
    CLINICAL OPHTHALMOLOGY, 2014, 8 : 1199 - 1202
  • [23] Comparison of Intravitreal Aflibercept Injection versus Intravitreal Ranibizumab Injection in Patients with Myopic Choroidal Neovascularization
    El Habbak, Ashraf
    El Nagar, Mohammed
    Tawfik, Tarek
    El Zaher, Mohamed Abd
    El Shiwy, Hoda
    Howaidy, Ahmed
    Falougy, Amr
    OPHTHALMOLOGICA, 2016, 236 : 38 - 39
  • [24] Comparison of the effects of intravitreal aflibercept, bevacizumab and ranibizumab on retinal function and vasculature after oxygen-induced retinopathy
    Lam, Wai Ching
    Tsang, Jessica
    Lo, Amy C. Y.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [25] Effect of Bevacizumab, Ranibizumab and Aflibercept on retinal pigment epithelium phagocytosis
    Fernandez, Patricia
    Hernandez, Maria
    Recalde, Sergio
    de Viteri, Manuel Saenz
    Belza, Idoia
    Moreno, Maite
    Bezunartea, Jaione
    Garcia-Layana, Alfredo
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [26] Ranibizumab and Aflibercept Levels in Breast Milk after Intravitreal Injection
    Juncal, Verena R.
    Paracha, Quratulain
    Bamakrid, Motaz
    Francisconi, Carolina L. M.
    Farah, Julia
    Kherani, Amin
    Muni, Rajeev H.
    OPHTHALMOLOGY, 2020, 127 (02) : 278 - 280
  • [27] Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion in Patients with Prior Treatment with Bevacizumab or Ranibizumab
    van Zyl, Tave
    Papakostas, Thanos D.
    Lim, Laurence Shen
    Miller, John B.
    Husain, Deeba
    Eliott, Dean
    Kim, Leo A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [28] Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab
    T D Papakostas
    L Lim
    T van Zyl
    J B Miller
    B S Modjtahedi
    C M Andreoli
    D Wu
    L H Young
    I K Kim
    D G Vavvas
    D D Esmaili
    D Husain
    D Eliott
    L A Kim
    Eye, 2016, 30 : 79 - 84
  • [29] Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab
    Papakostas, T. D.
    Lim, L.
    van Zyl, T.
    Miller, J. B.
    Modjtahedi, B. S.
    Andreoli, C. M.
    Wu, D.
    Young, L. H.
    Kim, I. K.
    Vavvas, D. G.
    Esmaili, D. D.
    Husain, D.
    Eliott, D.
    Kim, L. A.
    EYE, 2016, 30 (01) : 79 - 84
  • [30] VEGF Plasma levels after intravitreal injection of aflibercept and ranibizumab
    Kralinger, Martina T.
    Zehetner, Claus
    Waltl, Inga
    Kirchmayr, Rudolf
    Kieselbach, Gerhard F.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)